Pharmigene, Inc.
Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test… Read more
Pharmigene, Inc. (7595) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.124x
Based on the latest financial reports, Pharmigene, Inc. (7595) has a cash flow conversion efficiency ratio of -0.124x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-38.40 Million) by net assets (NT$310.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharmigene, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Pharmigene, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pharmigene, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharmigene, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
URBAS GRP.FINANC. EO 001
F:UZY
|
N/A |
|
Metallis Resources Inc
OTCQB:MTLFF
|
-1.850x |
|
Poxel SA
PA:POXEL
|
-0.124x |
|
Motorsport Gaming Us LLC
NASDAQ:MSGM
|
0.303x |
|
Kintech Electronics Co Ltd
TWO:6210
|
-0.081x |
|
H.Pio Co. Ltd.
KQ:357230
|
0.026x |
|
St-Georges Eco-Mining Corp
OTCQB:SXOOF
|
0.001x |
|
Xilam Animation
PA:XIL
|
0.207x |
Annual Cash Flow Conversion Efficiency for Pharmigene, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Pharmigene, Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$349.06 Million | NT$-44.82 Million | -0.128x | +26.45% |
| 2023-12-31 | NT$444.10 Million | NT$-77.54 Million | -0.175x | -152.78% |
| 2022-12-31 | NT$339.75 Million | NT$-23.47 Million | -0.069x | -36.75% |
| 2021-12-31 | NT$382.22 Million | NT$-19.30 Million | -0.051x | -61.92% |
| 2020-12-31 | NT$409.56 Million | NT$-12.78 Million | -0.031x | +82.80% |
| 2019-12-31 | NT$130.75 Million | NT$-23.71 Million | -0.181x | -- |